Search clinical trials for: Zatolmilast/ BPN14770

Total 10 results

Tetra Discovery Partners

Enrolling by invitation

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Tetra Discovery Partners

Recruiting

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

Fragile X Syndrome

United States
Tetra Discovery Partners

Recruiting

A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

Fragile X Syndrome

United States
Tetra Discovery Partners

Unknown

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

Alzheimer's Disease

United States
Tetra Discovery Partners

Completed

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

Alzheimer's Disease

United States
Tetra Discovery Partners

Completed

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

Alzheimer's Disease

United States
Tetra Discovery Partners

Withdrawn

A Phase 1, Open-Label, PET Study of T2310 & BPN14770

To Determine Brain Target Occupancy of BPN14770

United States
National Institute of Mental Health (NIMH)

Completed

Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)

Depression

United States
Tetra Discovery Partners

Completed

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

Fragile X Syndrome | Fra(X) Syndrome | FXS

United States
Tetra Discovery Partners

Completed

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Alzheimer Disease

United States

3

Subscribe